Pricing Log in Create free account
Friday 6 November 2026 Export EW’s income statement to Excel — free account

Edwards Lifesciences Corporation

EW Healthcare Medical Devices

Edwards Lifesciences Corporation’s revenue for fiscal 2025 (year ended December 2025) was $6.1 billion, up 11.5% from fiscal 2024.

Revenue
+10.5%
EPS
+4.60%
Free cash flow
−1.84%
Total debt
+0.10%

Quarter to September 2026, against a year earlier

101.94 1.12 +1.11%
Market cap
$58.1B
P/E
57.8×
Fwd P/E
36.5×
Dividend yield
—
F-score
5/9
Altman Z
11.54
Beneish M
−2.48
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Edwards Lifesciences Corporation 10-Q filed Nov 4, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 4:24 PM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors
Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Aug 4, 2026: 7 added · 31 modified; 10 with only figures updated

  1. Modified · Financial Highlights

    Our gross profit increased in the sixnine months ended JuneSeptember 30, 2026, driven primarily by our sales growth. Gross profit as a percentage of sales decreased primarily due to was consistent with the impact from foreign currency rate fluctuations partially offset by lower manufacturing expensessame period last year. The decrease in our diluted earnings per share in the sixnine months ended JuneSeptember 30, 2026, was driven primarily by an increase in our tax expense and certain impairment charges, partially offset by our aforementioned operational performance.

37 more changes in this Item, word by word, in Powerpack.